MAPK1 and breast cancer: Conversely, for the group of genderassociated female tumors (subtypesof breast cancer and endometrioid carcinoma of the uterine corpus), activationof both pathways was a positive prognostic biomarker of OS(Fig. 2A).Interestingly, conflicting trends were observed in the prognosticsignificance of ERK1 and ERK2 pathway activation for sarcoma and thyroidcancer.